POSB93 Conversion from Subcutaneous Trastuzumab to Trastuzumab-Dkst in Metastatic Breast Cancer: Comparative Cost-Efficiency Modelling between US and France
03 medical and health sciences
0302 clinical medicine
DOI:
10.1016/j.jval.2021.11.366
Publication Date:
2022-01-20T00:15:12Z
AUTHORS (5)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....